OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Esteva Discusses Adjuvant Trastuzumab in HER2+ Breast Cancer

June 27th 2018

Francisco J. Esteva, MD, PhD, medical oncologist, New York University’s Perlmutter Cancer Center, discusses adjuvant trastuzumab (Herceptin) in HER2-positive early breast cancer.

Dr. Katzel on Women Being Undertreated for Head and Neck Cancer

June 27th 2018

Jed Katzel, MD, Hematology, Kaiser Permanente Santa Clara Medical Center, discusses research presented at the 2018 ASCO Annual Meeting, which evaluated whether women are undertreated for head and neck cancer.

Dr. Yu on Treatment Intensification in Metastatic Castration-Sensitive Prostate Cancer

June 25th 2018

Evan Y. Yu, MD, professor, Department of Medicine, Division of Oncology, University of Washington, Seattle Cancer Care Alliance, discusses treatment intensification in patients with metastatic castration-sensitive prostate cancer.

Dr. Hong on Advances in Head and Neck Cancer

June 25th 2018

Waun K. Hong, MD, FACP, DMSc, division head, American Cancer Society Professor, Samsung Distinguished University Chair in Cancer Medicine, Department of Thoracic Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, and 2018 Giant of Cancer Care® in Head and Neck Cancer, discusses advances in the treatment of patients with head and neck cancer.

Dr. Sasine on CAR T-Cell Therapy in Ovarian Cancer

June 25th 2018

Joshua P. Sasine, MD, medical director, Chimeric Antigen Receptor T-Cell Program, David Geffen School of Medicine, University of California, Los Angeles, discusses chimeric antigen receptor (CAR) T- cell therapy in ovarian cancer.

Dr. Kopetz on the Importance of Molecular Testing in CRC

June 25th 2018

Scott Kopetz, MD, PhD, FACP, associate professor, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of molecular testing in colorectal cancer.

Dr. Raje Discusses the Tolerability of bb2121 in Myeloma

June 25th 2018

Noopur Raje, MD, director Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center, discusses the tolerability of bb2121 as a treatment for patients with multiple myeloma.

Dr. Mato Discusses a Phase II Trial of Umbralisib in CLL

June 25th 2018

Anthony R. Mato, MD, hematologic oncologist, director, CLL Program, Memorial Sloan Kettering Cancer Center, discusses a phase II trial of umbralisib in chronic lymphocytic leukemia.

Dr. Ramalingam on Avelumab Plus Lorlatinib in NSCLC

June 23rd 2018

Suresh S. Ramalingam, MD, deputy director, Winship Cancer Institute of Emory University, discusses the combination of avelumab (Bavencio) plus lorlatinib in patients with non–small cell lung cancer.

Dr. Galsky Discusses the Rationale for the IMvigor130 Study in Bladder Cancer

June 23rd 2018

Matthew Galsky, MD, professor of medicine, hematology, and medical oncology, Mount Sinai Hospital, discusses the rationale for the IMvigor130 study in metastatic bladder cancer.

Dr. Richardson Discusses the Results of the OPTIMISMM Trial in Myeloma

June 23rd 2018

Paul Richardson, MD, clinical program leader, director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, RJ Corman Professor of Medicine, Harvard Medical School, discusses the results of the OPTIMISMM trial in patients with multiple myeloma.

Dr. Novik on the Adoption of Biosimilars in Breast Cancer

June 23rd 2018

Yelena Novik, MD, associate professor, Department of Medicine, New York University’s Perlmutter Cancer Center, discusses the adoption of biosimilars in breast cancer.

Dr. Pecora on the Role of Stem Cell Transplant in Patients With Multiple Myeloma

June 23rd 2018

Andrew L. Pecora, MD, president of the Physician Services Division and chief innovation officer at Hackensack Meridian Health, discusses the role of stem cell transplant in patients with multiple myeloma.

Dr. Glaspy on Immunotherapy in Endometrial Cancer

June 23rd 2018

John A. Glaspy, MD, professor of medicine, Jonsson Comprehensive Cancer Center (JCCC), director, JCCC Clinical Research Unit and Women's Cancer Research Program, University of California, Los Angeles School of Medicine, discusses immunogenicity in endometrial cancer.

Dr. Goy on Prognostic Markers in Mantle Cell Lymphoma

June 22nd 2018

Andre Goy, MD, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses prognostic markers in mantle cell lymphoma (MCL).

Dr. Wingo on the Evolution of Surgery in Endometrial Cancer

June 22nd 2018

Shana Wingo, MD, gynecologic oncologist, Arizona Oncology, discusses the evolution of surgery in endometrial cancer.

Dr. Ali on the Future of Adjuvant Care for HER2+ Breast Cancer

June 21st 2018

Haythem Y. Ali, MD, senior medical oncologist, Henry Ford Hospital, discusses the future of adjuvant treatment for patients with HER2-positive breast cancer.

Dr. Ferris Discusses Nivolumab in Head and Neck Cancer

June 21st 2018

Robert Ferris, MD, PhD, vice chair for Clinical Operations, associate director for Translational Research, and co-leader of the Cancer Immunology Program at the University of Pittsburgh Cancer Institute, discusses nivolumab (Opdivo) in the treatment of patients with head and neck cancer.

Dr. Ascierto on the COLUMBUS Trial in Melanoma

June 21st 2018

Paolo A. Ascierto, MD, director of the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy at the National Tumor Institute Fondazione G. Pascale in Naples, discusses the COLUMBUS trial in melanoma.

Dr. Kolberg Discusses the Central Pathology Review of ABP 980

June 21st 2018

Hans-Christian Kolberg, MD, head, Department of Obstetrics and Gynecology, Breast Cancer Center, and Gynecologic Cancer Center at Marienhospital Bottrop, Klinik für Gynäkologie und Geburtshilfe, Bottrop, Germany, discusses the central pathology review of the trastuzumab (Herceptin) biosimilar ABP 980.